The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance
Open accessAbstract
One of the greatest obstacles to current cancer treatment efforts is the development of drug resistance by tumors. Despite recent advances in diagnostic practices and surgical interventions, many neoplasms demonstrate poor response to adjuvant or neoadjuvant radiation and chemotherapy. As a result, the prognosis for many patients afflicted with these aggressive cancers remains bleak. The insulin-like growth factor (IGF) signaling axis has been shown to play critical role in the development and progression of various tumors. Many basic science and translational studies have shown that IGF pathway modulators can have promising effects when used to treat various malignancies. There also exists a substantial body of recent evidence implicating IGF signaling dysregulation in the dwindling response of tumors to current standard-of-care therapy. By better understanding both the IGF-dependent and -independent mechanisms by which pathway members can influence drug sensitivity, we can eventually aim to use modulators of IGF signaling to augment the effects of current therapy. This review summarizes and synthesizes numerous recent investigations looking at the role of the IGF pathway in drug resistance. We offer a brief overview of IGF signaling and its general role in neoplasia, and then delve into detail about the many types of human cancer that have been shown to have IGF pathway involvement in resistance and/or sensitization to therapy. Ultimately, our hope is that such a compilation of evidence will compel investigators to carry out much needed studies looking at combination treatment with IGF signaling modulators to overcome current therapy resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Yang, B., Jia, Q., Ren, Z., Zhang, J., Jiang, X., Liang, L., Xue, T., Zhang, Q., Wang, Y., Zhang, L., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089686 · Cited by 33
RetractedJemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Critical nodes in signalling pathways: insights into insulin action
Taniguchi, C. M., Emanuelli, B., & Kahn, C. R. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1837 · Cited by 2,760 · cited 1×
“These MAPKs go on to phosphorylate and activate several targets, notably the transcription factor ELK1 which promotes gene expression and therefore cell growth.(3,6,7) The activity of the IGF ligands and receptors is modulated in a complex fashion by six IGF binding proteins (IGFBPs), named IGFBP-1 through IGFBP-6, re…”
BackgroundCirculating concentrations of insulin-like growth factor I and risk of breast cancer
Hankinson, S. E., Willett, W. C., Colditz, G. A., Hunter, D. J., Michaud, D. S., Deroo, B., Rosner, B., Speizer, F. E., & Pollak, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)10384-1 · Cited by 1,823
The evolution of gene regulation by transcription factors and microRNAs
Chen, K., & Rajewsky, N. (2007) · Nature Reviews Genetics · doi:10.1038/nrg1990 · Cited by 1,547
Insulin-like growth factors and neoplasia
Pollak, M. N., Schernhammer, E. S., & Hankinson, S. E. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1387 · Cited by 1,463
The insulin-like growth factor system and cancer
LeRoith, D., & Roberts, C. T. (2003) · Cancer Letters · doi:10.1016/s0304-3835(03)00159-9 · Cited by 1,124
Ma, J., Pollak, M. N., Giovannucci, E., Chan, J. M., Tao, Y., Hennekens, C. H., & Stampfer, M. J. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.7.620 · Cited by 1,119
The Insulin-Like Growth Factor-Binding Protein (IGFBP) Superfamily*
Hwa, V., Oh, Y., & Rosenfeld, R. G. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0382 · Cited by 1,079
The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal.
Kennedy, S. G., Wagner, A. J., Conzen, S. D., Jordán, J., Bellacosa, A., Tsichlis, P. N., & Hay, N. (1997) · Genes & Development · doi:10.1101/gad.11.6.701 · Cited by 1,074
Scher, H. I., & Sawyers, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4777 · Cited by 1,025
Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)
Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D., & Pollak, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1852 · Cited by 882
Goodenberger, M. L., & Jenkins, R. B. (2012) · Cancer Genetics · doi:10.1016/j.cancergen.2012.10.009 · Cited by 846
Riely, G. J., Pao, W., Pham, D., Li, A. R., Rizvi, N., Venkatraman, E. S., Zakowski, M. F., Kris, M. G., Ladanyi, M., & Miller, V. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1846 · Cited by 731
Jackman, D. M., Yeap, B. Y., Sequist, L. V., Lindeman, N., Holmes, A. J., Joshi, V. A., Bell, D. W., Huberman, M. S., Halmos, B., Rabin, M. S., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0462 · Cited by 584
KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma
Morris, J. P., Wang, S. C., & Hebrok, M. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2899 · Cited by 567
Guix, M., Faber, A. C., Wang, S. E., Olivares, M. G., Song, Y., Qu, S., Rinehart, C., Seidel, B., Yee, D., Arteaga, C. L., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34588 · Cited by 521
Jones, J. I., Gockerman, A., Busby, W. H., Wright, G., & Clemmons, D. R. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.22.10553 · Cited by 515
Massarweh, S., Osborne, C. K., Creighton, C. J., Qin, L., Tsimelzon, A., Huang, S., Weiss, H., Rimawi, M., & Schiff, R. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2707 · Cited by 488
Haimeur, A., Conseil, G., Deeley, R., & Cole, S. (2004) · Current Drug Metabolism · doi:10.2174/1389200043489199 · Cited by 485
Signalling by insulin and IGF receptors: supporting acts and new players
Siddle, K. (2011) · Journal of Molecular Endocrinology · doi:10.1530/jme-11-0022 · Cited by 456
Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling
Pouysségur, J., Volmat, V., & Lenormand, P. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01135-8 · Cited by 421
Androgen receptor: A key molecule in the progression of prostate cancer to hormone independence
Taplin, M., & Balk, S. P. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10653 · Cited by 390
Disrupting insulin-like growth factor signaling as a potential cancer therapy
Sachdev, D., & Yee, D. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0080 · Cited by 320
Disrupting Insulin-Like Growth Factor Signaling as a Potential Cancer Therapy
Sachdev, D., & Yee, D. (2008) · AACR Education book · doi:10.1158/aacr.edb-mct-06-0080 · Cited by 314
Obesity, type 2 diabetes, and cancer: the insulin and IGF connection
Cohen, D. H., & LeRoith, D. (2012) · Endocrine-Related Cancer · doi:10.1530/erc-11-0374 · Cited by 301
Shan, J., Shen, J., Liu, L., Xia, F., Xu, C., Duan, G., Xu, Y., Ma, Q., Yang, Z., Zhang, Q., et al. (2012) · Hepatology · doi:10.1002/hep.25745 · Cited by 296 · cited 1×
“In addition, IGF signaling seems to maintain the self-renewal capacity of cancer stem cells (CSCs) within these tumors.(93) In oxaliplatin-resistant HCC, the stemness of a subpopulation of tumor cells is associated with autocrine signaling of IGF1, whereas treatment with an IGF-1R inhibitor suppresses CSC-related mark…”
BackgroundLivingstone, C. (2013) · Endocrine-Related Cancer · doi:10.1530/erc-13-0231 · Cited by 296
Control of cell survival by IGF signaling pathways
Vincent, A. M., & Feldman, E. L. (2002) · Growth Hormone & IGF Research · doi:10.1016/s1096-6374(02)00017-5 · Cited by 289
Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib
Hantschel, O., Rix, U., & Superti-Furga, G. (2008) · Leukemia & Lymphoma · doi:10.1080/10428190801896103 · Cited by 256
Gallardo, A., Lerma, E., Escuin, D., Tibau, A., Muñoz, J., Ojeda, B., Barnadas, A., Adrover, E., Sánchez-Tejada, L., Giner, D., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.85 · Cited by 230
Function of the IGF-I Receptor in Breast Cancer
Surmacz, E. (2000) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1009523501499 · Cited by 214
IGF-1R as an anti-cancer target--trials and tribulations
Chen, H. X., & Sharon, E. (2013) · Chinese Journal of Cancer · doi:10.5732/cjc.012.10263 · Cited by 201
Gastric Cancer: Current Status of Diagnosis and Treatment
Takahashi, T., Saikawa, Y., & Kitagawa, Y. (2013) · Cancers · doi:10.3390/cancers5010048 · Cited by 196
Fuller, G. N., Rhee, C. H., Hess, K. R., Caskey, L. S., Wang, R., Bruner, J. M., Yung, W. K. A., & Zhang, W. (1999) · PubMed · Cited by 189
Interaction of IGF signaling and the androgen receptor in prostate cancer progression.
Wu, J. D., Haugk, K., Woodke, L., Nelson, P., Coleman, I., & Plymate, S. R. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20929 · Cited by 188
So, W. K. W., Chan, R. J., Chan, D. N. S., Hughes, B. G. M., Chair, S. Y., Choi, K. C., & Chan, C. W. H. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.04.005 · Cited by 184
Zhang, Y., Moerkens, M., Ramaiahgari, S., de Bont, H., Price, L., Meerman, J., & van de Water, B. (2011) · Breast Cancer Research · doi:10.1186/bcr2883 · Cited by 171
Kuhn, D. J., Berkova, Z., Jones, R. J., Woessner, R., Bjorklund, C. C., Ma, W., Davis, R. E., Lin, P., Wang, H., Madden, T. L., et al. (2012) · Blood · doi:10.1182/blood-2011-10-386789 · Cited by 170
Targeting the Insulin-like Growth Factor Receptor-1R Pathway for Cancer Therapy
Zha, J., & Lackner, M. R. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2232 · Cited by 166
Body Image and Quality of Life After Head and Neck Cancer Surgery
Dropkin, M. J. (1999) · Cancer Practice · doi:10.1046/j.1523-5394.1999.76006.x · Cited by 161
Targeting PI3 kinase in cancer
Bauer, T. M., Patel, M. R., & Infante, J. R. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.09.006 · Cited by 160
Can we unlock the potential of IGF-1R inhibition in cancer therapy?
King, H., Aleksic, T., Haluska, P., & Macaulay, V. M. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.07.004 · Cited by 142
IGF1 Receptor Signaling Regulates Adaptive Radioprotection in Glioma Stem Cells
Osuka, S., Sampetrean, O., Shimizu, T., Saga, I., Onishi, N., Sugihara, E., Okubo, J., Fujita, S., Takano, S., Matsumura, A., et al. (2013) · Stem Cells · doi:10.1002/stem.1328 · Cited by 139
Angelo, J. C. (2008) · Frontiers in bioscience · doi:10.2741/2925 · Cited by 133
Ye, X., Zhu, H., Bai, W., Wang, T., Wang, L., Chen, Y., Yang, A., & Jia, L. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-134 · Cited by 133
Murakami, A., Takahashi, F., Nurwidya, F., Kobayashi, I., Minakata, K., Hashimoto, M., Nara, T., Kato, M., Tajima, K., Shimada, N., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086459 · Cited by 131
Targeting the PI3K/AKT/mTOR Signaling Axis in Children with Hematologic Malignancies
Barrett, D., Brown, V. I., Grupp, S. A., & Teachey, D. T. (2012) · Pediatric Drugs · doi:10.1007/bf03262236 · Cited by 130
Koti, M., Gooding, R. J., Nuin, P. A. S., Haslehurst, A., Crane, C. A., Weberpals, J. I., Childs, T. J., Bryson, P., Dharsee, M., Evans, K. G., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-549 · Cited by 126
Bartalucci, N., Tozzi, L., Bogani, C., Martinelli, S., Rotunno, G., Villeval, J., & Vannucchi, A. M. (2013) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12162 · Cited by 126
Su, Y., Wagner, E. R., Luo, Q., et al. (2011) · Oncogene · doi:10.1038/onc.2011.97 · Cited by 124
Fagan, D. H., Uselman, R. R., Sachdev, D., & Yee, D. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0684 · Cited by 118
Han, S., Li, Z., Master, L., Master, Z., & Wu, A. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.435 · Cited by 116
Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies
Tasian, S. K., Teachey, D. T., & Rheingold, S. R. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00108 · Cited by 116
Suzuki, H., Igarashi, S., Nojima, M., Maruyama, R., Yamamoto, E., Kai, M., Akashi, H., Watanabe, Y., Yamamoto, H., Sasaki, Y., et al. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp179 · Cited by 107
Vázquez‐Martín, A., Cufí, S., Oliveras‐Ferraros, C., Torres-Garcia, V. Z., Corominas-Faja, B., Cuyàs, E., Bonavia, R., Visa, J., Martín-Castillo, B., Barrajón‐Catalán, E., et al. (2013) · Scientific Reports · doi:10.1038/srep02560 · Cited by 100
Chemotherapy dosing in overweight and obese patients with cancer
Lyman, G. H., & Sparreboom, A. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.108 · Cited by 98
Hedgehog/GLI1 regulates IGF dependent malignant behaviors in glioma stem cells
Hsieh, A., Ellsworth, R., & Hsieh, D. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22433 · Cited by 97
Knowlden, J. M., Jones, H. E., Barrow, D., Gee, J. M. W., Nicholson, R. I., & Hutcheson, I. R. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9763-9 · Cited by 95
Peled, N., Wynes, M. W., Ikeda, N., Ohira, T., Yoshida, K., Qian, J., Ilouze, M., Brenner, R. M., Kato, Y., Mascaux, C., et al. (2013) · Cellular Oncology · doi:10.1007/s13402-013-0133-9 · Cited by 93
Fox, E. M., Kuba, M. G., Miller, T. W., Davies, B. R., & Arteaga, C. L. (2013) · Breast Cancer Research · doi:10.1186/bcr3449 · Cited by 92
The Insulin-Like Growth Factor Pathway in Lung Cancer
Dziadziuszko, R., Camidge, D. R., & Hirsch, F. R. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31818180f5 · Cited by 90
Hyperglycaemia-induced chemoresistance of prostate cancer cells due to IGFBP2
Biernacka, K. M., Uzoh, C. C., Zeng, L., Persad, R. A., Bahl, A. K., Gillatt, D. A., Perks, C. M., & Holly, J. M. P. (2013) · Endocrine Related Cancer · doi:10.1530/erc-13-0077 · Cited by 90
The Role of IGF-1R in Pediatric Malignancies
Kim, S. Y., Toretsky, J. A., Scher, D., & Helman, L. J. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0189 · Cited by 90
Jameson, M. J., Beckler, A. D., Taniguchi, L. E., Allak, A., VanWagner, L. B., Lee, N. G., Thomsen, W. C., Hubbard, M. A., & Thomas, C. Y. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0294 · Cited by 88
Duan, Z., Choy, E., Harmon, D. C., Cao, Y., Ryu, K., Schwab, J. H., Mankin, H. J., & Hornicek, F. J. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0115 · Cited by 84
Cortés-Sempere, M., Miguel, M. P. D., Pernía, O., Rodríguez‐Antolín, C., de Castro, J., Nistal, M., Conde, E., López‐Ríos, F., Belda-Iniesta, C., Perona, R., et al. (2012) · Oncogene · doi:10.1038/onc.2012.146 · Cited by 79
miR-503 represses CUG-binding protein 1 translation by recruiting CUGBP1 mRNA to processing bodies
Cui, Y., Xiao, L., Rao, J. N., Zou, T., Liu, L., Chen, Y., Turner, D. J., Gorospe, M., & Wang, J. (2011) · Molecular Biology of the Cell · doi:10.1091/mbc.e11-05-0456 · Cited by 74
Self-citationDevelopment of Nanoscale Approaches for Ovarian Cancer Therapeutics and Diagnostics
Engelberth, S. A., Hempel, N., & Bergkvist, M. (2014) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2014011455 · Cited by 73
Jeannot, V., Busser, B., Brambilla, E. M., Wislez, M., Robin, B., Cadranel, J. L., Coll, J., & Hurbin, A. (2013) · International Journal of Cancer · doi:10.1002/ijc.28594 · Cited by 66
Faye, M. D., Beug, S. T., Graber, T. E., Earl, N., Xiang, X., Wild, B., Langlois, S. D., Michaud, J., Cowan, K. N., Korneluk, R. G., et al. (2014) · Oncogene · doi:10.1038/onc.2014.90 · Cited by 66
Kawai, M., Breggia, A., DeMambro, V., Shen, X., CANALIS, E. M., Bouxsein, M., Beamer, W. G., Clemmons, D. R., & Rosen, C. J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.193334 · Cited by 65
Role of Insulin-Like Growth Factor-1 Signaling Pathway in Cisplatin-Resistant Lung Cancer Cells
Sun, Y., Zheng, S., Torossian, A., Speirs, C. K., Schleicher, S. M., Giacalone, N. J., Carbone, D. P., Zhao, Z., & Lu, J. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2011.06.1999 · Cited by 65
Lu, H., Wang, L., Gao, W. X., Meng, J., Dai, B., Wu, S., Minna, J. D., Roth, J. A., Hofstetter, W. L., Swisher, S. G., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0233 · Cited by 64
Luther, G. A., Lamplot, J. D., Chen, X., et al. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.05.002 · Cited by 61
Suda, K., Mizuuchi, H., Sato, K., Takemoto, T., Iwasaki, T., & Mitsudomi, T. (2014) · International Journal of Cancer · doi:10.1002/ijc.28737 · Cited by 57
Singh, R. K., Gaikwad, S. M., Jinager, A., Chaudhury, S., Maheshwari, A., & Ray, P. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.08.023 · Cited by 57
Beltran, P. J., Calzone, F. J., Mitchell, P., Chung, Y.-A., Cajulis, E. E., Moody, G. E., Belmontes, B., Li, C.-M., Vonderfecht, S. L., Velculescu, V. E., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3448 · Cited by 49
High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia
Kühnl, A., Kaiser, M., Neumann, M., Fransecky, L. R., Heesch, S., Radmacher, M. D., Marcucci, G., Bloomfield, C. D., Hofmann, W., Thiel, E., et al. (2011) · Leukemia Research · doi:10.1016/j.leukres.2011.08.006 · Cited by 46
Wang, Y., Wang, Z.-X., Qiu, Y., Xiong, J., Chen, Y., Miao, D., & De, W. (2009) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-009-0064-y · Cited by 45
Self-citationSharma, J., Gray, K. P., Evan, C. P., Nakabayashi, M., Fichorova, R. N., Rider, J. R., Mucci, L. A., Kantoff, P. W., & Sweeney, C. J. (2013) · The Prostate · doi:10.1002/pros.22744 · Cited by 45
Shen, K., Cui, D., Sun, L., Lü, Y., Han, M., & Liu, J. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24080 · Cited by 44
Insulin-Like Growth Factor 2 Silencing Restores Taxol Sensitivity in Drug Resistant Ovarian Cancer
Brouwer‐Visser, J., Lee, J., McCullagh, K., Cossio, M. J., Wang, Y., & Huang, G. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100165 · Cited by 39
Verhagen, H. J. M. P., de Leeuw, D. C., Roemer, M. G. M., Denkers, F., Pouwels, W., Rutten, A. P., Celie, P. H. N., Ossenkoppele, G. J., Schuurhuis, G. J., & Smit, L. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.268 · Cited by 36
Targeting insulin-like growth factor in breast cancer therapeutics
Karamouzis, M. V., & Papavassiliou, A. G. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.02.010 · Cited by 34
Laranjeira, A. B. A., de Vasconcellos, J. F., Sodek, L., Spago, M. C., Fornazim, M. C., Tone, L. G., Brandalise, S. R., Nowill, A. E., & Yunes, J. A. (2011) · Leukemia · doi:10.1038/leu.2011.289 · Cited by 33
Wang, Y., Xiong, J., Wang, S., Yu, Y., Wang, B., Chen, Y., Shi, H.-F., & Qiu, Y. (2010) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-010-0453-2 · Cited by 33
Luk, F., Yu, Y. Y., Walsh, W. R., & Yang, J. (2011) · Cancer Investigation · doi:10.3109/07357907.2011.606252 · Cited by 33
The new concepts on overcoming drug resistance in lung cancer
Dong, X., Xu, C., Lei, P., & Zhang, W. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s60672 · Cited by 32
Downregulation of IGFBP2 is associated with resistance to IGF1R therapy in rhabdomyosarcoma
Kang, Z., Yu, Y., Zhu, Y. J., Davis, S. R., Walker, R. L., Meltzer, P. S., Helman, L. J., & Cao, L. (2013) · Oncogene · doi:10.1038/onc.2013.509 · Cited by 32
Winder, T. L., Giamas, G., Wilson, P. M., Zhang, W., Yang, D., Bohanes, P. O., Ning, Y., Gerger, A., Stebbing, J., & Lenz, H. J. (2013) · The Pharmacogenomics Journal · doi:10.1038/tpj.2013.8 · Cited by 31
Breast cancer and possible mechanisms of therapy resistance
Florea, A., & Büsselberg, D. (2013) · Journal of Local and Global Health Science · doi:10.5339/jlghs.2013.2 · Cited by 30
High-grade gliomas: reality and hopes
Mirimanoff, R. (2014) · 癌症:英文版 · doi:10.5732/cjc.013.10215 · Cited by 30
Feng, W., Liu, Y., Bellail, A. C., Olson, J. J., Sun, S. Y., Lu, G., Ding, L., Yuan, C., Wang, G., & Hao, C. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.02.005 · Cited by 29
Deciphering the Role of Insulin-Like Growth Factor-I Receptor in Trastuzumab Resistance
Nahta, R. (2012) · Chemotherapy Research and Practice · doi:10.1155/2012/648965 · Cited by 29
Chen, M. Y., Clark, A. J., Chan, D. C., Ware, J. L., Holt, S. E., Chidambaram, A., Fillmore, H. L., & Broaddus, W. C. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0374-7 · Cited by 29
Okamura, J., Huang, Y., Moon, D., Brait, M., Chang, X., & Sook-Kim, M. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.13.3.18695 · Cited by 28
Impact of targeting insulin-like growth factor signaling in head and neck cancers
Limesand, K. H., Chibly, A. M., & Fribley, A. M. (2013) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2013.06.001 · Cited by 26
Liu, S., Meng, X., Chen, H., Liu, W., Miller, T. W., Murph, M. M., Lu, Y., Zhang, F., Gagea, M., Arteaga, C. L., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2022 · Cited by 25
Tagoug, I., Jordheim, L. P., Herveau, S., Matera, E., Huber, A., Chettab, K., Manié, S. N., & Dumontet, C. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3134 · Cited by 21
Fidler, M. J., Basu, S., Buckingham, L. E., Walters, K. K., McCormack, S., Batus, M., Coon, J. S., & Bonomi, P. (2012) · PubMed · Cited by 17
QI, H. W., Shen, Z., & Fan, L. H. (2011) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2011.324 · Cited by 16
Eccleston, A., & Dhand, R. (2006) · Nature · doi:10.1038/441423a · Cited by 16
Volkova, E., Robinson, B. A., Willis, J. A., Currie, M. J., & Dachs, G. U. (2013) · Oncology Letters · doi:10.3892/ol.2013.1710 · Cited by 16
Global Igfbp1 deletion does not affect prostate cancer development in a c-Myc transgenic mouse model
Gray, A., Aronson, W. J., Barnard, R. J., Mehta, H. H., Wan, J., SAID, J. W., Cohen, P., & Galet, C. (2011) · Journal of Endocrinology · doi:10.1530/joe-11-0240 · Cited by 15
Hsu, H.-H., Cheng, L.-H., Ho, T., Kuo, W., Lin, Y.-M., Chen, M., Lee, N., Tsai, F., Tsai, K.-H., & Huang, C. (2013) · Tumor Biology · doi:10.1007/s13277-013-1041-3 · Cited by 15
Investigation of IGF2, Hedgehog and fusion gene expression profiles in pediatric sarcomas
de Souza, R. R., Oliveira, I. D., Paniago, M. D. G., et al. (2014) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2014.04.002 · Cited by 13
Choi, Y. J., Park, G. M., Rho, J. K., Kim, S. Y., So, G. S., Kim, H. R., Choi, C., & Lee, J. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081393 · Cited by 12
Cancer stem cells in head and neck squamous cell carcinoma.
Szafarowski, T., & Szczepański, M. J. (2014) · Otolaryngologia polska = The Polish otolaryngology · doi:10.1016/j.otpol.2013.10.010 · Cited by 11
Chemotherapeutic drug resistance in the management of head and neck cancer
Bier, H. (1993) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/bf00171524 · Cited by 10
The two opposite facets of arsenic: toxic and anticancer drug
Florea, A., & Büsselberg, D. (2013) · Journal of Local and Global Health Science · doi:10.5339/jlghs.2013.1 · Cited by 9
Cited by
Liao, J., Wei, Q., Zou, Y., Fan, J., Song, D., Cui, J., Zhang, W., Zhu, Y., Ma, C., Hu, X., et al. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000471945 · Cited by 2,742
Self-citationHigh-throughput single-cell ChIP-seq identifies heterogeneity of chromatin states in breast cancer
Grosselin, K., Durand, A., Marsolier, J., Poitou, A., Marangoni, E., Nemati, F., Dahmani, A., Lameiras, S., Reyal, F., Frenoy, O., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0424-9 · Cited by 466
Phosphoinositide 3-Kinase/Akt Signaling and Redox Metabolism in Cancer
Koundouros, N., & Poulogiannis, G. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00160 · Cited by 415
Alam, S., Hasan, M. K., Neaz, S., Hussain, N., Hossain, M. F., & Rahman, T. (2021) · Diabetology · doi:10.3390/diabetology2020004 · Cited by 323
Hyperinsulinemia in Obesity, Inflammation, and Cancer
Zhang, A. M. Y., Wellberg, E. A., Kopp, J. L., & Johnson, J. D. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0250 · Cited by 305
Metadata
- Authors
- Denduluri, S. K., Idowu, O., Wang, Z., Liao, Z., Yan, Z., Mohammed, M. K., Ye, J., Wei, Q., Wang, J., Zhao, L., & Luu, H. H.
- Venue
- Genes & Diseases
- Publisher
- Elsevier BV
- Published
- 2015-03
- Volume
- 2
- Issue
- 1
- Pages
- 13-25
- ISSN
- 2352-3042 (ISSN-L)
- OpenAlex
- W2059641782
- Cited by
- 331
- References
- 111
- FWCI
- 17.71
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.